Table 3. Endpoint of PFS and OS in patients with CNS relapse grouped by treatment allocation, and according to drug received Idarubicin vs Mitoxantrone.

	n	3 yr PFS (95% CI)	p-value	3 yr OS (95% CI)	p-value
Intended SCT	91
Idarubicin	34	22·2% (9·9, 37·4)		34·0 (18·7, 49·9)
Mitoxantrone	57	55·0% (39·4, 68·1)	0·02	63·0% (46·7, 75·5)	0·02
Intended No SCT	19
Idarubicin	6	66·7% (19·5, 90·4)		66·7% (19·5, 90·4)
Mitoxantrone	13	61·5% (26·6, 83·7)	0·90	68·6% (21·3, 91·2)	0·81
Actual SCT	60
Idarubicin	21	36·4% (16·6, 56·6)		35·7% (16·1, 56·0)
Mitoxantrone	39	72·2% (52·8, 84·7)	0·02	76·0% (55·6, 87·9)	0·01
Actual No SCT	32
Idarubicin	14	28·6% (8·8, 52·4)		50·0% (22·9, 72·2)
Mitoxantrone	18	50·4% (22·6, 72·9)	0·20	59·2% (17·6, 85·4)	0·39